GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » ROA %

PolyPeptide Group AG (XSWX:PPGN) ROA % : -5.29% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. PolyPeptide Group AG's annualized Net Income for the quarter that ended in Dec. 2023 was CHF-32.4 Mil. PolyPeptide Group AG's average Total Assets over the quarter that ended in Dec. 2023 was CHF612.3 Mil. Therefore, PolyPeptide Group AG's annualized ROA % for the quarter that ended in Dec. 2023 was -5.29%.

The historical rank and industry rank for PolyPeptide Group AG's ROA % or its related term are showing as below:

XSWX:PPGN' s ROA % Range Over the Past 10 Years
Min: -8.3   Med: 8.5   Max: 9.59
Current: -8.3

During the past 6 years, PolyPeptide Group AG's highest ROA % was 9.59%. The lowest was -8.30%. And the median was 8.50%.

XSWX:PPGN's ROA % is ranked worse than
69.2% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.68 vs XSWX:PPGN: -8.30

PolyPeptide Group AG ROA % Historical Data

The historical data trend for PolyPeptide Group AG's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG ROA % Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial 8.60 9.16 9.59 1.29 -7.97

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.57 3.46 -0.84 -11.70 -5.29

Competitive Comparison of PolyPeptide Group AG's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's ROA % distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's ROA % falls into.



PolyPeptide Group AG ROA % Calculation

PolyPeptide Group AG's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-48.512/( (568.219+649.862)/ 2 )
=-48.512/609.0405
=-7.97 %

PolyPeptide Group AG's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-32.392/( (574.698+649.862)/ 2 )
=-32.392/612.28
=-5.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


PolyPeptide Group AG  (XSWX:PPGN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-32.392/612.28
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-32.392 / 355.612)*(355.612 / 612.28)
=Net Margin %*Asset Turnover
=-9.11 %*0.5808
=-5.29 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


PolyPeptide Group AG ROA % Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines